Related to Horizon and Promega Ally on Cancer Models for Development of Targeted Drug Therapies

• Horizon Applies Gene Editing to Huntington’s Disease
  
• NTRC Forges Drug Discovery Services Partnership with Carna
  
• Crown Takes a Second Look at Horizon
  
• Horizon Gains Patents to Cell Lines that Model Genetic Mutations Seen in Cancer
  
• Horizon Acquires Human Isogenic Cell Models of DNA Damage Repair from University of Minnesota
  
• Horizon Teams Up with U.K.’s ICR to Identify Lethality Genes for Specific Cancers
  
• Cylene Looks to Horizon to Identify Genetic Basis of Response to Oral Anticancer Drug
  
• Horizon and University of Washington Partner to Apply Gene Editing to IPSCs
  
• Horizon and Fox Chase Establish Gene-Editing Collaboration and Center of Excellence
  
• Horizon Raises $18.6M in Series C Financing to Broaden Utility of X-Man Platform
  
• Horizon Deal Supports Boehringer Ingelheim Drug Discovery
  
• New Centers of Excellence on the Horizon in Asia
  
• Horizon, AstraZeneca Seek Kinase-Targeting Cancer Drugs
  
• Horizon Licenses Minnesota Uni IP to Boost Rate of rAAV Gene Editing Platform
  
• Horizon Obtains Human Cancer Cell Models from University of Pittsburgh
  
• NCI/NHGRI Taps Horizon's Gene-Editing Platform
  
• Horizon, RFUMS to Generate Human Cell Cystic Fibrosis Model
  
• Horizon Discovery to Support H3 Biomedicine’s Cancer Target Validation Studies
  
• TGen Gains Open Access to Horizon’s Gene-Engineering and Isogenic Cancer Cell Line Platform
  
• Novartis Signs Four-Year Deal with Horizon for Custom-Generated X-Man Cancer Models